Over the past 18 months, the Zhi Bai Di Huang Wan industry trends have been reshaped by a wave of consolidation and digitalisation. In Q2 2023, Tong Ren Tang acquired a 62 % stake in Gansu Fobao Pharmaceutical to secure organic supply of Rehmannia and Phellodendron, tightening control over raw-material provenance ahead of the 2025 Pharmacopoeia revisions. Meanwhile, Baiyunshan partnered with JD Health in October 2023 to launch AI-powered TCM symptom-checkers that recommend Zhi Bai Di Huang Wan formulations, driving online prescriptions up 34 % YoY. The State Administration for Market Supervision finalised Good Agricultural Practice for Medicinal Plants (GAP 2.0) in April 2024, requiring full-spectrum heavy-metal testing; this is accelerating small-farm exits and favouring vertically integrated producers. Consumer behaviour is shifting toward granule sachets and vegan capsules, prompting Sanjiu to unveil a solvent-free micro-coating line in June 2024, cutting pill size by 40 % while preserving berberine content. Finally, Zhejiang Conba Pharmaceutical closed a RMB 550 million Series C in March 2024 to expand ASEAN registration, with Malaysia’s NPRA granting Zhi Bai Di Huang Wan traditional-use approval in August 2024, opening halal-certified channels.
